View Future GrowthFluidra 과거 순이익 실적과거 기준 점검 4/6Fluidra의 수입은 연평균 -9.4%의 비율로 감소해 온 반면, Machinery 산업은 수입이 연평균 6.7% 증가했습니다. 매출은 연평균 0.7%의 비율로 증가해 왔습니다. Fluidra의 자기자본이익률은 10.6%이고 순이익률은 7.7%입니다.핵심 정보-9.43%순이익 성장률-9.20%주당순이익(EPS) 성장률Machinery 산업 성장률19.41%매출 성장률0.75%자기자본이익률10.59%순이익률7.73%다음 순이익 업데이트30 Jul 2026최근 과거 실적 업데이트Reported Earnings • Mar 29Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Machinery industry in Italy.Reported Earnings • Feb 27Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Machinery industry in Italy.공시 • Jan 12+ 3 more updatesFluidra, S.A. to Report Q1, 2026 Results on May 06, 2026Fluidra, S.A. announced that they will report Q1, 2026 results on May 06, 2026모든 업데이트 보기Recent updates공시 • May 29Fluidra Announces Chief Financial Officer ChangesFluidra announced that its Board of Directors has appointed Juan Graham as Chief Financial Officer. Graham will join the company and Fluidra’s Executive Committee on 1 June 2026, working closely with Xavier Tintoré over the coming months to ensure a smooth and well-coordinated transition. Xavier will step down as Chief Financial Officer on 1 August 2026 and will continue supporting the company until the end of the year as part of the transition. The appointment follows a planned and orderly succession process linked to Xavier Tintoré’s decision to begin a new professional and personal chapter after 16 years as Fluidra’s CFO. Juan Graham brings more than 25 years of international experience in senior finance roles, combining strong functional expertise with hands-on operational leadership. He spent nearly two decades at Johnson & Johnson, where he held senior leadership positions across consumer health, supply chain operations, treasury, mergers and acquisitions, and global finance. His experience includes leading finance organizations of significant scale and complexity, including supporting a business with more than $14 billion in annual revenue. Most recently, Graham served as CFO of U.S.-listed companies including FibroGen and Perspective Therapeutics, where he led finance, investor relations, IT and strategic planning functions through periods of transformation and growth. Tintoré has been a key figure in Fluidra’s transformation over the past 16 years, playing a central role not only in the company’s financial leadership, but also across strategy, investor relations, integration and transformation initiatives and several corporate functions. He was instrumental through some of the company’s most important milestones, including the merger with Zodiac, Fluidra’s inclusion in the IBEX 35, the company’s international expansion and numerous strategic acquisitions.공시 • May 28Fluidra Appoints Juan Graham to the Executive Committee, Effective 1 June 2026Fluidra announced that Juan Graham will join the company and Fluidra’s Executive Committee on 1 June 2026, working closely with Xavier Tintoré over the coming months to ensure a smooth and well-coordinated transition. Juan Graham brings more than 25 years of international experience in senior finance roles, combining strong functional expertise with hands-on operational leadership. He spent nearly two decades at Johnson & Johnson, where he held senior leadership positions across consumer health, supply chain operations, treasury, mergers and acquisitions, and global finance. His experience includes leading finance organizations of significant scale and complexity, including supporting a business with more than $14 billion in annual revenue. Most recently, Graham served as CFO of U.S.-listed companies including FibroGen and Perspective Therapeutics, where he led finance, investor relations, IT and strategic planning functions through periods of transformation and growth.Declared Dividend • May 20Dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.7%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Buy Or Sell Opportunity • May 08Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €19.53. The fair value is estimated to be €25.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Declared Dividend • Apr 28Final dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 29Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Machinery industry in Italy.Buy Or Sell Opportunity • Mar 27Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.6% to €20.02. The fair value is estimated to be €26.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공시 • Mar 27Fluidra, S.A., Annual General Meeting, May 06, 2026Fluidra, S.A., Annual General Meeting, May 06, 2026. Location: ac hotel sant cugat, placa de xavier cugat, sant cugat del valles, barcelona., SpainDeclared Dividend • Mar 08Final dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 27% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €20.90, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Machinery industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €28.67 per share.Reported Earnings • Feb 27Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Machinery industry in Italy.Buy Or Sell Opportunity • Feb 27Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €22.64. The fair value is estimated to be €29.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공시 • Feb 26+ 1 more updateFluidra, S.A. Proposes Dividend for 2025, Payable on 14 July 2026 and 10 December 2026 RespectivelyFluidra, S.A. announced that the Board proposed a 2025 dividend distribution of 65 Euro cents per share, up 8% and subject to shareholder approval. If approved, Fluidra will make a first payment of 32 Euro cents per share on 14 July 2026 and a second payment of 33 Euro cents per share on 10 December 2026.공시 • Jan 12+ 3 more updatesFluidra, S.A. to Report Q1, 2026 Results on May 06, 2026Fluidra, S.A. announced that they will report Q1, 2026 results on May 06, 2026Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €27.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Machinery industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €26.24 per share.Buy Or Sell Opportunity • Nov 28Now 20% overvaluedOver the last 90 days, the stock has fallen 6.9% to €22.74. The fair value is estimated to be €18.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.Upcoming Dividend • Nov 24Upcoming dividend of €0.24 per shareEligible shareholders must have bought the stock before 01 December 2025. Payment date: 03 December 2025. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Italian dividend payers (4.8%). Higher than average of industry peers (1.3%).공시 • Oct 30Fluidra Reaffirms Its Guidance for Full Year 2025Fluidra reaffirmed its guidance for full year 2025. The company remains on track to deliver its full-year 2025 guidance with expected sales between €2,160 and 2,220 million.공시 • Jul 31Fluidra, S.A. Updates Earnings Guidance for the Year 2025Fluidra, S.A. updated earnings guidance for the year 2025. For the period, the company now expects sales to be between €2,160 and €2,220 million.공시 • May 07Fluidra, S.A. Reaffirms Earnings Guidance for the Year 2025Fluidra, S.A. reaffirmed earnings guidance for the year 2025. The company is maintaining 2025 guidance as move into the key months of the pool season.공시 • Mar 28+ 1 more updateFluidra, S.A., Annual General Meeting, May 07, 2025Fluidra, S.A., Annual General Meeting, May 07, 2025. Location: ac hotel sant cugat, placa de xavier cugat, sant cugat del valles, barcelona Spain매출 및 비용 세부 내역Fluidra가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:1FDR 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 262,250174470031 Dec 252,248176465030 Sep 252,248178480030 Jun 252,216162467031 Mar 252,198149473031 Dec 242,161138452030 Sep 242,120129460030 Jun 242,094122424031 Mar 242,080110417031 Dec 232,106114417030 Sep 232,10589406030 Jun 232,18898444031 Mar 232,336126441031 Dec 222,449160451030 Sep 222,497210476030 Jun 222,500245419031 Mar 222,392260432031 Dec 212,234252390030 Sep 212,087241409030 Jun 211,945216337031 Mar 211,718162312031 Dec 201,52696290030 Sep 201,48761291030 Jun 201,42335289031 Mar 201,40913294031 Dec 191,4078301030 Sep 191,3778344030 Jun 191,367-36334031 Mar 191,190-40319031 Dec 181,056-35269030 Sep 18919-25252030 Jun 1880027204031 Mar 1879329201031 Dec 1779831198030 Sep 1779836203030 Jun 1778633194031 Mar 1776028196031 Dec 1673424191030 Sep 1672323195030 Jun 1671221183031 Mar 1668919182031 Dec 1566713174030 Sep 156418174030 Jun 1562971630양질의 수익: 1FDR는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 1FDR의 현재 순 이익률 (7.7%)은 지난해 (6.8%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1FDR의 수익은 지난 5년 동안 연평균 9.4% 감소했습니다.성장 가속화: 지난 1년간 1FDR 의 수익 증가율(16.6%)은 연간 평균(-9.4%)을 초과합니다.수익 대 산업: 1FDR의 지난 1년 수익 증가율(16.6%)은 Machinery 업계의 4.1%를 상회했습니다.자기자본이익률높은 ROE: 1FDR의 자본 수익률(10.6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 07:03종가2026/06/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Fluidra, S.A.는 24명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBanco de Sabadell. S.A.Alejandro Conde FraisoliBanco Santandernull nullBanco Santander21명의 분석가 더 보기
Reported Earnings • Mar 29Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Machinery industry in Italy.
Reported Earnings • Feb 27Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Machinery industry in Italy.
공시 • Jan 12+ 3 more updatesFluidra, S.A. to Report Q1, 2026 Results on May 06, 2026Fluidra, S.A. announced that they will report Q1, 2026 results on May 06, 2026
공시 • May 29Fluidra Announces Chief Financial Officer ChangesFluidra announced that its Board of Directors has appointed Juan Graham as Chief Financial Officer. Graham will join the company and Fluidra’s Executive Committee on 1 June 2026, working closely with Xavier Tintoré over the coming months to ensure a smooth and well-coordinated transition. Xavier will step down as Chief Financial Officer on 1 August 2026 and will continue supporting the company until the end of the year as part of the transition. The appointment follows a planned and orderly succession process linked to Xavier Tintoré’s decision to begin a new professional and personal chapter after 16 years as Fluidra’s CFO. Juan Graham brings more than 25 years of international experience in senior finance roles, combining strong functional expertise with hands-on operational leadership. He spent nearly two decades at Johnson & Johnson, where he held senior leadership positions across consumer health, supply chain operations, treasury, mergers and acquisitions, and global finance. His experience includes leading finance organizations of significant scale and complexity, including supporting a business with more than $14 billion in annual revenue. Most recently, Graham served as CFO of U.S.-listed companies including FibroGen and Perspective Therapeutics, where he led finance, investor relations, IT and strategic planning functions through periods of transformation and growth. Tintoré has been a key figure in Fluidra’s transformation over the past 16 years, playing a central role not only in the company’s financial leadership, but also across strategy, investor relations, integration and transformation initiatives and several corporate functions. He was instrumental through some of the company’s most important milestones, including the merger with Zodiac, Fluidra’s inclusion in the IBEX 35, the company’s international expansion and numerous strategic acquisitions.
공시 • May 28Fluidra Appoints Juan Graham to the Executive Committee, Effective 1 June 2026Fluidra announced that Juan Graham will join the company and Fluidra’s Executive Committee on 1 June 2026, working closely with Xavier Tintoré over the coming months to ensure a smooth and well-coordinated transition. Juan Graham brings more than 25 years of international experience in senior finance roles, combining strong functional expertise with hands-on operational leadership. He spent nearly two decades at Johnson & Johnson, where he held senior leadership positions across consumer health, supply chain operations, treasury, mergers and acquisitions, and global finance. His experience includes leading finance organizations of significant scale and complexity, including supporting a business with more than $14 billion in annual revenue. Most recently, Graham served as CFO of U.S.-listed companies including FibroGen and Perspective Therapeutics, where he led finance, investor relations, IT and strategic planning functions through periods of transformation and growth.
Declared Dividend • May 20Dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.7%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Buy Or Sell Opportunity • May 08Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €19.53. The fair value is estimated to be €25.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Declared Dividend • Apr 28Final dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.3%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 29Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Machinery industry in Italy.
Buy Or Sell Opportunity • Mar 27Now 26% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.6% to €20.02. The fair value is estimated to be €26.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공시 • Mar 27Fluidra, S.A., Annual General Meeting, May 06, 2026Fluidra, S.A., Annual General Meeting, May 06, 2026. Location: ac hotel sant cugat, placa de xavier cugat, sant cugat del valles, barcelona., Spain
Declared Dividend • Mar 08Final dividend of €0.26 announcedShareholders will receive a dividend of €0.26. Ex-date: 10th July 2026 Payment date: 14th July 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 27% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €20.90, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Machinery industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €28.67 per share.
Reported Earnings • Feb 27Full year 2025 earnings released: EPS: €0.93 (vs €0.73 in FY 2024)Full year 2025 results: EPS: €0.93 (up from €0.73 in FY 2024). Revenue: €2.25b (up 4.1% from FY 2024). Net income: €176.0m (up 28% from FY 2024). Profit margin: 7.8% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Machinery industry in Italy.
Buy Or Sell Opportunity • Feb 27Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €22.64. The fair value is estimated to be €29.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공시 • Feb 26+ 1 more updateFluidra, S.A. Proposes Dividend for 2025, Payable on 14 July 2026 and 10 December 2026 RespectivelyFluidra, S.A. announced that the Board proposed a 2025 dividend distribution of 65 Euro cents per share, up 8% and subject to shareholder approval. If approved, Fluidra will make a first payment of 32 Euro cents per share on 14 July 2026 and a second payment of 33 Euro cents per share on 10 December 2026.
공시 • Jan 12+ 3 more updatesFluidra, S.A. to Report Q1, 2026 Results on May 06, 2026Fluidra, S.A. announced that they will report Q1, 2026 results on May 06, 2026
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €27.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Machinery industry in Italy. Simply Wall St's valuation model estimates the intrinsic value at €26.24 per share.
Buy Or Sell Opportunity • Nov 28Now 20% overvaluedOver the last 90 days, the stock has fallen 6.9% to €22.74. The fair value is estimated to be €18.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
Upcoming Dividend • Nov 24Upcoming dividend of €0.24 per shareEligible shareholders must have bought the stock before 01 December 2025. Payment date: 03 December 2025. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Italian dividend payers (4.8%). Higher than average of industry peers (1.3%).
공시 • Oct 30Fluidra Reaffirms Its Guidance for Full Year 2025Fluidra reaffirmed its guidance for full year 2025. The company remains on track to deliver its full-year 2025 guidance with expected sales between €2,160 and 2,220 million.
공시 • Jul 31Fluidra, S.A. Updates Earnings Guidance for the Year 2025Fluidra, S.A. updated earnings guidance for the year 2025. For the period, the company now expects sales to be between €2,160 and €2,220 million.
공시 • May 07Fluidra, S.A. Reaffirms Earnings Guidance for the Year 2025Fluidra, S.A. reaffirmed earnings guidance for the year 2025. The company is maintaining 2025 guidance as move into the key months of the pool season.
공시 • Mar 28+ 1 more updateFluidra, S.A., Annual General Meeting, May 07, 2025Fluidra, S.A., Annual General Meeting, May 07, 2025. Location: ac hotel sant cugat, placa de xavier cugat, sant cugat del valles, barcelona Spain